NORVIR
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
NORVIR by Abbott is [see microbiology ( ) ] . Approved for combination with other antiretroviral agents for the treatment of pediatric patients with hiv-1 infection. First approved in 1996.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an oral small-molecule HIV protease inhibitor approved in 1996 for treatment of HIV infection. It works by inhibiting HIV protease, preventing viral replication and spread. The drug is now primarily used as a pharmacokinetic booster in combination antiretroviral regimens rather than as monotherapy.
LOE Approaching
Declining
Late-lifecycle product with moderate competitive pressure (30/100); team focus shifting from growth to managed decline and lifecycle extension strategies.
Mechanism of Action
[see Microbiology ( ) ] .
Clinical Trials (1)
Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada
Started Jan 2008
35 enrolled
HIV Infections
Career Relevance
Working on NORVIR offers limited career growth opportunity given LOE-approaching status and minimal linked job openings; roles focus on managed decline, payer relations, and authorized generic strategy rather than launch or expansion. Career progression would benefit from transition planning to growth-stage HIV or other therapeutic areas.
Worked on NORVIR at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.